Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
BB Biotech AG (BION.SW)
Kusnacht, CH
BB Biotech AG is an investment fund overseen by Bellevue Asset Management AG. This fund allocates capital to publicly traded companies worldwide, with a primary focus on firms pioneering modern biotechnology, specifically in the development of medications and diagnostic tools. The construction of its investment portfolio is guided by a fundamental analysis approach. Established on November 9, 1993, BB Biotech AG is headquartered in Switzerland.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.91% | -1.13% | -1.13% | -7.32% | -3.11% | +0.69% | +48.72% | +4.80% | -45.81% | -11.46% | +106.29% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+318,848.6% ★ Q2'25: -292,943.8% (vs Q2'24)
-
EPS growth Biotechnology: +29.7%+136.6% ★ Q2'25: -14.4% (vs Q2'24)
-
FCF margin FCF growth · Biotechnology: +16.2%+67.5% Q2'25: +64.0% (vs Q2'24)
-
EBIT margin Biotechnology: +0.0%+72.0% ★ Q2'25: +6.5% (vs Q2'24)
-
ROIC Biotechnology: -16.1%— Q2'25: -1.1% (vs Q2'24)
-
Share dilution Biotechnology: -3.4%0.0% ★ Q2'25: +0.6% (vs Q2'24)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×1.46× ★
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
4.0K
est: 21.0K (-81.0%)
|
35.0K
est: 192.96M (-100.0%)
|
111.63M
est: -80.80M (+238.2%)
|
616.88M
est.
|
1.28B
1.28B – 1.28B
+107.3% YoY
|
1.28B
1.28B – 1.28B
+0.0% YoY
|
1.28B
1.28B – 1.28B
+0.0% YoY
|
| EBITDA |
-357.29M
est: 3.0K (-12,025,882.6%)
|
-201.26M
est: 27.30M (-837.2%)
|
80.24M
est: -11.43M (+801.9%)
|
87.27M
est.
|
180.95M
180.95M – 180.95M
+107.3% YoY
|
180.95M
180.95M – 180.95M
+0.0% YoY
|
180.95M
180.95M – 180.95M
+0.0% YoY
|
| EBIT |
-43.01M
est: -599.00 (-7,180,701.3%)
|
-34.60M
est: -5.51M (-528.4%)
|
80.33M
est: 2.31M (+3,383.6%)
|
-17.60M
est.
|
-36.50M
-36.50M – -36.50M
-107.3% YoY
|
-36.50M
-36.50M – -36.50M
+0.0% YoY
|
-36.50M
-36.50M – -36.50M
+0.0% YoY
|
| Net Income |
-357.81M
est: -92.17M (-288.2%)
|
-206.61M
est: 234.08M (-188.3%)
|
75.90M
est: 204.25M (-62.8%)
|
180.95M
est.
|
54.10M
54.10M – 54.10M
-70.1% YoY
|
37.35M
37.35M – 37.35M
-31.0% YoY
|
32.42M
32.42M – 32.42M
-13.2% YoY
|
| SGA |
5.31M
est: 6.27M (-15.3%)
|
5.79M
est: 57.61B (-100.0%)
|
27.23M
est: -24.12B (+100.1%)
|
184.18B
est.
|
381.87B
381.87B – 381.87B
+107.3% YoY
|
381.87B
381.87B – 381.87B
+0.0% YoY
|
381.87B
381.87B – 381.87B
+0.0% YoY
|
| EPS |
-6.50
est: -1.68 (-286.7%)
|
-3.77
est: 4.27 (-188.3%)
|
1.38
est: 3.73 (-63.0%)
|
3.30
est.
|
0.99
0.99 – 0.99
-70.1% YoY
|
0.68
0.68 – 0.68
-31.0% YoY
|
0.59
0.59 – 0.59
-13.2% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-15 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Swiss Dividend ETF (CH) CHDVD.SW | 0.62% | 60.55M | 0.15% |
| 2 | iShares Core SPI(R) ETF (CH) CHSPI.SW | 0.15% | 10.46M | 0.10% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Daniel Koller | Head of Biotech, Portfolio Manager and Member of Executive Board | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BION.SW
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
